Human cytomegalovirus resistance to antiviral drugs

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 873-883

  Gilbert, C ^a   Boivin, G ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BENZIMIDAVIR; CIDOFOVIR; CYTIDINE DERIVATIVE; DEOXYGUANOSINE DERIVATIVE; DNA POLYMERASE; FOMIVIRSEN; FOSCARNET SODIUM; GANCICLOVIR; GW 275175X; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; PRODRUG; PROTEIN KINASE; PYROPHOSPHORIC ACID DERIVATIVE; TOMEGLOVIR; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTHRALGIA; CYTOMEGALOVIRUS INFECTION; DNA DNA HYBRIDIZATION; DRUG BIOAVAILABILITY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; FLOW CYTOMETRY; GASTROINTESTINAL INFECTION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE COUNT; MALAISE; MONONUCLEOSIS; NEUTROPENIA; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETINITIS; RISK FACTOR; SHORT SURVEY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG RESISTANCE, VIRAL; HUMANS; MUTATION;

EID: 14744270979     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.873-883.2005     Document Type: Short Survey

References (139)

1. Baldanti, F., D. Lilleri, G. Campanini, G. Comolli, A. L. Ridolfo, S. Rusconi, and G. Gerna. 2004. Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response. J. Antimicrob. Chemother. 53:536-539.
2. Baldanti, F., D. Michel, L. Simoncini, M. Heuschmid, A. Zimmermann, R. Minisini, P. Schaarschmidt, T. Schmid, G. Gerna, and T. Mertens. 2002. Mutations in the UL97 ORF of ganciclovir-resistant clinical cytomegalovirus isolates differentially affect GCV phosphorylation as determined in a recombinant vaccinia virus system. Antivir. Res. 54:59-67.
3. Baldanti, F., S. Paolucci, A. Parisi, L. Meroni, and G. Gerna. 2002. Emergence of multiple drug-resistant human cytomegalovirus variants in 2 patients with human immunodeficiency virus infection unresponsive to highly active antiretroviral therapy. Clin. Infect. Dis. 34:1146-1149.
4. Baldanti, F., E. Silini, A. Sarasini, C. L. Talarico, S. C. Stanat, K. K. Biron, M. Furione, F. Bono, G. Palu, and G. Gerna. 1995. A three-nucleotide deletion in the UL97 open reading frame is responsible for the ganciclovir resistance of a human cytomegalovirus clinical isolate. J. Virol. 69:796-800.
5. Baldanti, F., M. R. Underwood, S. C. Stanat, K. K. Biron, S. Chou, A. Sarasini, E. Silini, and G. Gerna. 1996. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J. Virol. 70:1390-1395.
6. Baldanti, F., M. R. Underwood, C. L. Talarico, L. Simoncini, A. Sarasini, K. K. Biron, and G. Gerna. 1998. The Cys607→Tyr change in the UL97 phosphotransferase confers ganciclovir resistance to two human cytomegalovirus strains recovered from two immunocompromised patients. Antimicrob. Agents Chemother. 42:444-446.
7. Balfour, H. H., Jr. 1999. Antiviral drugs. N. Engl. J. Med. 340:1255-1268.
8. Benz, C., G. Holz, D. Michel, S. Awerkiew, V. Dries, D. Stippel, T. Goeser, and D. H. Busch. 2003. Viral escape and T-cell immunity during ganciclovir treatment of cytomegalovirus infection: case report of a pancreatico-renal transplant recipient. Transplantation 75:724-727.
9. Bernad, A., L. Blanco, J. M. Lazaro, G. Martin, and M. Salas. 1989. A conserved 3′-5′ exonuclease active site in prokaryotic and eukaryotic DNA polymerases. Cell 59:219-228.
10. Bhorade, S. M., N. S. Lurain, A. Jordan, J. Leischner, J. Villanueva, R. Durazo, S. Creech, W. T. Vigneswaran, and E. R. Garrity. 2002. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients. J. Heart Lung Transplant. 21:1274-1282.
11. Bidanset, D. J., J. R. Beadle, W. B. Wan, K. Y. Hostetler, and E. R. Kern. 2004. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J. Infect. Dis. 190:499-503.
12. Biron, K. K. 1991. Ganciclovir-resistant human cytomegalovirus clinical isolates; resistance mechanisms and in vitro susceptibility to antiviral agents. Transplant. Proc. 23:162-167.
13. Biron, K. K., J. A. Fyfe, S. C. Stanat, L. K. Leslie, J. B. Sorrell, C. U. Lambe, and D. M. Coen. 1986. A human cytomegalovirus mutant resistant to the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc. Natl. Acad. Sci. USA 83:8769-8773.
14. Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka. 2002. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46:2365-2372.
15. Biron, K. K., S. C. Stanat, J. B. Sorrell, J. A. Fyfe, P. M. Keller, C. U. Lambe, and D. J. Nelson. 1985. Metabolic activation of the nucleoside analog 9-([2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc. Natl. Acad. Sci. USA 82:2473-2477.
16. Blanco, L., A. Bernad, M. A. Blasco, and M. Salas. 1991. A general structure for DNA-dependent DNA polymerases. Gene 100:27-38.
17. Boeckh, M., and G. Boivin. 1998. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin. Microbiol. Rev. 11:533-554.
18. Boeckh, M., W. Leisenring, S. R. Riddell, R. A. Bowden, M.-L. Huang, D. Myerson, T. Stevens-Ayers, M. E. D. Flowers, T. Cunningham. and L. Corey. 2003. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood 101:407-414.
19. Boivin, G., S. Chou, M. R. Quirk, A. Erice, and M. C. Jordan. 1996. Detection of ganciclovir resistance mutations and quantitation of cytomegalovirus (CMV) DNA in leukocytes of patients with fatal disseminated CMV disease. J. Infect. Dis. 173:523-528.
20. Boivin, G., C. Gilbert, A. Gaudreau, I. Greenfield, R. Sudlow, and N. A. Roberts. 2001. Rate of emergence of cytomegalovirus (CMV) mutations in leukocytes of patients with acquired immunodeficiency syndrome who are receiving valganciclovir as induction and maintenance therapy for CMV retinitis. J. Infect. Dis. 184:1598-1602.
21. Boivin, G., N. Goyette, C. Gilbert, N. Roberts, K. Macey, C. Paya, M. D. Pescovitz, A. Humar, E. Dominguez, K. Washburn, E. Blumberg, B. Alexander, R. Freeman, N. Heaton, and E. Covington. 2004. Absence of cytomegalovirus- resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J. Infect. Dis. 189:1615-1618.
22. Boppana, S. B., R. F. Pass, W. J. Britt, S. Stagno, and C. A. Alford. 1992. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr. Infect. Dis. J. 11:93-99.
23. Bowen, E. F., J. M. Cherrington, P. D. Lamy, P. D. Griffiths, M. A. Johnson, and V. C. Emery. 1999. Quantitative changes in cytomegalovirus DNAemia and genetic analysis of the UL97 and UL54 genes in AIDS patients receiving cidofovir following ganciclovir therapy. J. Med. Virol. 58:402-407.
24. Buerger, I., J. Reefschlaeger, W. Bender, P. Eckenberg, A. Popp, O. Weber, S. Graeper, H. D. Klenk, H. Ruebsamen-Waigmann, and S. Hallenberger. 2001. A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. J. Virol. 75:9077-9086.
25. Chee, M. S., G. L. Lawrence, and B. G. Barrell. 1989. Alpha-, beta- and gammaherpesviruses encode a putative phosphotransferase. J. Gen. Virol. 70:1151-1160.
26. Cherrington, J. M., M. D. Fuller, P. D. Lamy, R. Miner, J. P. Lalezari, S. Nuessle, and W. L. Drew. 1998. In vitro antiviral susceptibilities of isolates from cytomegalovirus retinitis patients receiving first- or second-line cidofovir therapy: relationship to clinical outcome. J. Infect. Dis. 178:1821-1825.
27. Chou, S., A. Erice, M. C. Jordan, G. M. Vercellotti, K. R. Michels, C. L. Talarico, S. C. Stanat, and K. K. Biron. 1995. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance. J. Infect. Dis. 171:576-583.
28. Chou, S., N. S. Lurain, K. D. Thompson, R. C. Miner, and W. L. Drew. 2003. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J. Infect. Dis. 188:32-39.
29. Chou, S., N. S. Lurain, A. Weinberg, G. Y. Cai, P. L. Sharma, and C. S. Crumpacker. 1999. Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Antimicrob. Agents Chemother. 43:1500-1502.
30. Chou, S., G. Marousek, S. Guentzel, S. E. Follansbee, M. E. Poscher, J. P. Lalezari, R. C. Miner, and W. L. Drew. 1997. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J. Infect. Dis. 176:786-789.
31. Chou, S., G. Marousek, D. M. Parenti, S. M. Gordon, A. G. Lavoy, J. G. Ross, R. C. Miner, and W. L. Drew. 1998. Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy. J. Infect. Dis. 178:526-530.
32. Chou, S., G. I. Marousek, A. E. Senters, M. G. Davis, and K. K. Biron. 2004. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 78:7124-7130.
33. Chou, S., and C. L. Meichsner. 2000. A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir. Antimicrob. Agents Chemother. 44:183-185.
34. Chou, S., R. H. Waldemer, A. E. Senters, K. S. Michels, G. W. Kemble, R. C. Miner, and W. L. Drew. 2002. Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir. J. Infect. Dis. 185:162-169.
35. Chrisp, P., and S. P. Clissold. 1991. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 41:104-129.
36. Cihlar, T., and M. S. Chen. 1996. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 50:1502-1510.
37. Cihlar, T., M. Fuller, and J. Cherrington. 1998. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J. Virol. 72:5927-5936.
38. Cihlar, T., M. D. Fuller, A. S. Mulato, and J. M. Cherrington. 1998. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 248:382-393.
39. Dankner, W. M., D. Scholl, S. C. Stanat, M. Martin, R. L. Sonke, and S. A. Spector. 1990. Rapid antiviral DNA-DNA hybridization assay for human cytomegalovirus. J. Virol. Methods 28:293-298.
40. Deayton, J., A. Mocroft, P. Wilson, V. C. Emery, M. A. Johnson, and P. D. Griffiths. 1999. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS 13:1203-1206.
41. Drew, W. 2003. Cytomegalovirus disease in the highly active antiretroviral therapy era. Curr. Infect. Dis. Rep. 5:257-265.
42. Drew, W. L., R. Anderson, W. Lang, R. C. Miner, G. Davis, and J. Lalezari. 1995. Failure of high-dose oral acyclovir to suppress CMV viruria or induce ganciclovir-resistant CMV in HIV antibody positive patients. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:289-291.
43. Drew, W. L., R. C. Miner, D. F. Busch, S. E. Follansbee, J. Gullett, S. G. Mehalko, S. M. Gordon, W. F. Owen, Jr., T. R. Matthews, and W. C. Buhles. 1991. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J. Infect. Dis. 163:716-719.
44. Eckle, T., L. Prix, G. Jahn, T. Klingebiel, R. Handgretinger, B. Selle, and K. Hamprecht. 2000. Drug-resistant human cytomegalovirus infection in children after allogeneic stem cell transplantation may have different clinical outcomes. Blood 96:3286-3289.
45. Emery, V. C., A. V. Cope, E. F. Bowen, D. Gor, and P. D. Griffiths. 1999. The dynamics of human cytomegalovirus replication in vivo. J. Exp. Med. 190:177-182.
46. Emery, V. C., and A. F. Hassan-Walker. 2002. Focus on new drugs in development against human cytomegalovirus. Drugs 62:1853-1858.
47. Erice, A., N. Borrell, W. Li, W. J. Miller, and H. H. Balfour, Jr. 1998. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis. J. Infect. Dis. 178:531-534.
48. Erice, A., S. Chou, K. K. Biron, S. C. Stanat, H. H. Balfour, Jr., and M. C. Jordan. 1989. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients, N. Engl. J. Med. 320:289-293.
49. Erice, A., C. Gil-Roda, J. L. Perez, H. H. Balfour, K. J. Sannerud, M. N. Hanson, G. Boivin, and S. Chou. 1997. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J. Infect. Dis. 175:1087-1092.
50. Forrest, D. M., E. Seminari, R. S. Hogg, B. Yip, J. Raboud, L. Lawson, P. Phillips, M. T. Schechter, M. V. O'Shaughnessy, and J. S. Montaner. 1998. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. Clin. Infect. Dis. 27:1379-1385.
51. Gerna, G., F. Baldanti, M. Zavattoni, A. Sarasini, E. Percivalle, and M. G. Revello. 1992. Monitoring of ganciclovir sensitivity of multiple human cytomegalovirus strains coinfecting blood of an AIDS patient by an immediate-early antigen plaque assay. Antivir. Res. 19:333-345.
52. Gerna, G., A. Sarasini, D. Lilleri, E. Percivalle, M. Torsellini, F. Baldanti, and M. G. Revello. 2003. In vitro model for the study of the dissociation of increasing antigenemia and decreasing DNAemia and viremia during treatment of human cytomegalovirus infection with ganciclovir in transplant recipients. J. Infect. Dis. 188:1639-1647.
53. Gilbert, C., J. Bestman-Smith, and G. Boivin. 2002. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist. Update 5:88-114.
54. Gilbert, C., and G. Boivin. 2003. Discordant phenotypes and genotypes of cytomegalovirus (CMV) in patients with AIDS and relapsing CMV retinitis. AIDS 17:337-341.
55. Gilbert, C., J. Handfield, E. Toma, R. Lalonde, M. G. Bergeron, and G. Boivin. 1998. Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS 12:125-129.
56. Gilbert, C., J. Roy, R Bélanger, R. Delage, C. Béliveau, C. Demers, and G. Boivin. 2001. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients. Antimicrob. Agents Chemother. 45:3669-3671.
57. Hamprecht, K., T. Eckle, L. Prix, C. Faul, H. Einsele, and G. Jahn. 2003. Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J. Infect. Dis. 187:139-143.
58. Hanks, S. K., A. M. Quinn, and T. Hunter. 1988. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241:42-52.
59. Hanson, M. N., L. C. Preheim, S. Chou, C. L. Talarico, K. K. Biron, and A. Erice. 1995. Novel mutation in the UL97 gene of a clinical cytomegalovirus strain conferring resistance to ganciclovir. Antimicrob. Agents Chemother. 39:1204-1205.
60. Hu, H., D. A. Jabs, M. S. Forman, B. K. Martin, J. P. Dunn, D. V. Weinberg, and J. L. Davis. 2002. Comparison of cytomegalovirus (CMV) UL97 gene sequences in the blood and vitreous of patients with acquired immunodeficiency syndrome and CMV retinitis. J. Infect. Dis. 185:861-867.
61. Hwang, Y. T., B. Y. Liu, D. M. Coen, and C. B. Hwang. 1997. Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J. Virol. 71:7791-7798.
62. Ijichi, O., D. Michel, T. Mertens, K. Miyata, and Y. Eizuru. 2002. GCV resistance due to the mutation A594P in the cytomegalovirus protein UL97 is partially reconstituted by a second mutation at D605E. Antivir. Res. 53:135-142,
63. Jabs, D. A., C. Enger, J. P. Dunn, and M. Forman. 1998. Cytomegalovirus retinitis and viral resistance: ganciclovir resistance. J. Infect. Dis. 177:770-773.
64. Jabs, D. A., C. Enger, M. Forman, and J. P. Dunn. 1998. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. Antimicrob. Agents Chemother. 42:2240-2244.
65. Jabs, D. A., B. K. Martin, M. S. Forman, J. P. Dunn, J. L. Davis, D. V. Weinberg, K. K. Biron, and F. Baldanti. 2001. Mutations conferring ganciclovir resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J. Infect. Dis. 183:333-337.
66. Jabs, D. A., B. K. Martin, M. S. Forman, J. P. Dunn, J. L. Davis, D. V. Weinberg, K. K. Biron, F. Baldanti, and H. Hu. 2001. Longitudinal observations on mutations conferring ganciclovir resistance in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: The Cytomegalovirus and Viral Resistance Study Group Report Number 8. Am. J. Ophthalmol. 132:700-710.
67. Jacobson, M. A., H. Stanley, C. Holtzer, T. P. Margolis, and E. T. Cunningham. 2000. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30:231-233.
68. Kariya, M., S. Mori, and Y. Eizuru. 2000. Comparison of human cytomegalovirus DNA polymerase activity for ganciclovir-resistant and -sensitive clinical strains. Antivir. Res. 45:115-122.
69. Kesson, A., F. Zeng, A. Cunningham, and W. Rawlinson. 1998. The use of flow cytometry to detect antiviral resistance in human cytomegalovirus. J. Virol. Methods 71:177-186.
70. Komazin, G., R. G. Ptak, B. T. Emmer, L. B. Townsend, and J. C. Drach. 2003. Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J. Virol. 77:11499-11506.
71. Koszalka, G. W., N. W. Johnson, S. S. Good, L. Boyd, S. C. Chamberlain, L. B. Townsend, J. C. Drach, and K. K. Biron. 2002. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 46:2373-2380.
72. Krosky, P. M., M. C. Baek, and D. M. Coen. 2003. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77:905-914.
73. Kruger, R. M., W. D. Shannon, M. Q. Arens, J. P. Lynch, G. A. Storch, and E. P. Trulock. 1999. The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 68:1272-1279.
74. Kuhn, F. J., and C. W. Knopf. 1996. Herpes simplex virus type 1 DNA polymerase. Mutational analysis of the 3′-5′-exonuclease domain. J. Biol. Chem. 271:29245-29254.
75. Kuo, I. C., Y. Imai, C. Shum, D. F. Martin, B. D. Kuppermann, and T. P. Margolis. 2003. Genotypic analysis of cytomegalovirus retinitis poorly responsive to intravenous ganciclovir but responsive to the ganciclovir implant. Am. J. Ophthalmol. 135:20-25.
76. Lalezari, J. P., J. A. Aberg, L. H. Wang, M. B. Wire, R. Miner, W. Snowden, C. L. Talarico, S. Shaw, M. A. Jacobson, and W. L. Drew. 2002. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46:2969-2976.
77. Landry, M. L., S. Stanat, K. Biron, D. Brambilla, W. Britt, J. Jokela, S. Chou, W. L. Drew, A. Erice, B. Gilliam, N. Lurain, J. Manischewitz, R. Miner, M. Nokta, P. Reichelderfer, S. Spector, A. Weinberg, B. Yen-Lieberman, and C. Crumpacker. 2000. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob. Agents Chemother. 44:688-692.
78. Larder, B. A., S. D. Kemp, and G. Darby. 1987. Related functional domains in virus DNA polymerases. EMBO J. 6:169-175.
79. Li, W., F. Anwar, J. Jesurrun, and A. Erice. 1999. Cytomegalovirus UL97 and glycoprotein B (gB) sequences in tissues from immunocompromised patients with ganciclovir-resistant virus infection. Scand. J. Infect. Dis. 31:549-553.
80. Limaye, A. P. 2002. Ganciclovir-resistant cytomegalovirus in organ transplant recipients. Clin. Infect. Dis. 35:866-872.
81. Limaye, A. P., L. Corey, D. M. Koelle, C. L. Davis, and M. Boeckh. 2000. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 356:645-649.
82. Limaye, A. P., G. Raghu, D. M. Koelle, J. Ferrenberg, M. L. Huang, and M. Boeckh. 2002. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J. Infect. Dis. 185:20-27.
83. Littler, E., A. D. Stuart, and M. S. Chee. 1992. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 358:160-162.
84. Liu, W., B. D. Kuppermann, D. F. Martin, R. A. Wolitz, and T. P. Margolis. 1998. Mutations in the cytomegalovirus UL97 gene associated with ganciclovir-resistant retinitis. J. Infect. Dis. 177:1176-1181.
85. Ljungman, P. 1996. Cytomegalovirus infections in transplant patients. Scand. J. Infect. Dis. Suppl. 100:59-63.
86. Lowance, D., H. H. Neumayer, C. M. Legendre, J. P. Squifflet, J. Kovarik, P. J. Brennan, D. Norman, R. Mendez, M. R. Keating, G. L. Coggon, A. Crisp, and I. C. Lee. 1999. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N. Engl. J. Med. 340:1462-1470.
87. Lurain, N. S., S. M. Bhorade, K. J. Pursell, R. K. Avery, V. V. Yeldandi, C. M. Isada, E. S. Robert, D. J. Kohn, M. Q. Arens, E. R. Garrity, A. J. Taege, M. G. Mullen, K. M. Todd, J. W. Bremer, and B. Yen-Lieberman. 2002. Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients. J. Infect. Dis. 186:760-768.
88. Lurain, N. S., L. E. Spafford, and K. D. Thompson. 1994. Mutation in the UL97 open reading frame of human cytomegalovirus strains resistant to ganciclovir. J. Virol. 68:4427-4431.
89. Lurain, N. S., K. D. Thompson, E. W. Holmes, and G. S. Read. 1992. Point mutations in the DNA polymerase gene of human cytomegalovirus that result in resistance to antiviral agents. J. Virol. 66:7146-7152.
90. Lurain, N. S., A. Weinberg, C. S. Crumpacker, and S. Chou. 2001. Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing. Antimicrob. Agents Chemother. 45:2775-2780.
91. Marschall, M., M. Freitag, P. Suchy, D. Romaker, R. Kupfer, M. Hanke, and T. Stamminger. 2003. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311:60-71.
92. McSharry, J. J., A. McDonough, B. Olson, S. Hallenberger, J. Reefschlaeger, W. Bender, and G. L. Drusano. 2001. Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir. Antimicrob. Agents Chemother. 45:2925-2927.
93. McSharry, J. M., N. S. Lurain, G. L. Drusano, A. Landay, J. Manischewitz, M. Nokta, M. O'Gorman, H. M. Shapiro, A. Weinberg, P. Reichelderfer, and C. Crumpacker. 1998. Flow cytometric determination of ganciclovir susceptibilities of human cytomegalovirus clinical isolates. J. Clin. Microbiol. 36:958-964.
94. Metzger, C., D. Michel, K. Schneider, A. Luske, H. J. Schlicht, and T. Mertens. 1994. Human cytomegalovirus UL97 kinase confers ganciclovir susceptibility to recombinant vaccinia virus. J. Virol. 68:8423-8427.
95. Michel, D., S. Hohn, T. Haller, D. Jun, and T. Mertens. 2001. Aciclovir selects for ganciclovir-cross-resistance of human cytomegalovirus in vitro that is only in part explained by known mutations in the UL97 protein. J. Med. Virol. 65:70-76.
96. Michel, D., and T. Mertens. 2004. The UL97 protein kinase of human cytomegalovirus and homologues in other herpesviruses: impact on virus and host. Biochim. Biophys. Acta 1697:169-180.
97. Michel, D., I. Pavic, A. Zimmermann, E. Haupt, K. Wunderlich, M. Heuschmid, and T. Mertens. 1996. The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J. Virol. 70:6340-6346.
98. Mousavi-Jazi, M., L. Schloss, W. L. Drew, A. Linde. R. C. Miner, J. Harmenberg, B. Wahren, and M. Brytting. 2001. Variations in the cytomegalovirus DNA polymerase and phosphotransferase genes in relation to foscarnet and ganciclovir sensitivity. J. Clin. Virol. 23:1-15.
99. Mulamba, G. B., A. Hu, R. F. Azad, K. P. Andersen, and D. M. Coen. 1998. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob. Agents Chemother. 42:971-973.
100. Mylonakis, E., W. M. Kallas, and J. A. Fishman. 2002. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients. Clin. Infect. Dis. 34:1337-1341.
101. Nguyen, Q., R. Champlin, S. Giralt, K. Rolston, I. Raad, K. Jacobson, C. Ippoliti, D. Hecht, J. Tarrand, M. Luna, and E. Whimbey. 1999. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin. Infect. Dis. 28:618-623.
102. Nichols, W., and M. Boeckh. 2001. Cytomegalovirus infections. Curr. Treat. Options Infect. Dis. 3:78-91.
103. Nichols, W. G., L. Corey, T. Gooley, W. L. Drew, R. Miner, M. Huang, C. Davis, and M. Boeckh. 2001. Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes. Blood 97:867-874.
104. O'Sullivan, C. E., W. L. Drew, D. J. McMullen, R. Miner, J. Y. Lee, R. A. Kaslow, J. G. Lazar, and M. S. Saag. 1999. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. J. Infect. Dis. 180:847-849.
105. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
106. Paya, C. V., J. A. Wilson, M. J. Espy, I. G. Sia, M. J. Debernardi, T. F. Smith, R. Patel, G. Jenkins, W. S. Harmsen, D. J. Vanness, and R. H. Wiesner. 2002. Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. J. Infect. Dis. 185:854-860.
107. Pescovitz, M. D., J. Rabkin, R. M. Merion, C. V. Paya, J. Pirsch, R. B. Freeman, J. O'Grady, C. Robinson, Z. To, K. Wren, L. Banken, W. Buhles, and F. Brown. 2000. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob. Agents Chemother. 44:2811-2815.
108. Prichard, M. N., N. Gao, S. Jairath, G. Mulamba, P. Krosky, D. M. Coen, B. O. Parker, and G. S. Pari. 1999. A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J. Virol. 73:5663-5670.
109. Razonable, R. R., and C. V. Paya. 2002. β-Herpesviruses in transplantation. Rev. Med. Microbiol. 13:163-176.
110. Razonable, R. R., A. Rivero, A. Rodriguez, J. Wilson, J. Daniels, G. Jenkins, T. Larson, W. C. Hellinger, J. R. Spivey, and C. V. Paya. 2001. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J. Infect. Dis. 184:1461-1464.
111. Reefschlaeger, J., W. Bender, S. Hallenberger, O. Weber, P. Eckenberg, S. Goldmann, M. Haerter, I. Buerger, J. Trappe, J. A. Herrington, D. Haebich, and H. Ruebsamen-Waigmann. 2001. Novel non-nucleoside inhibitors of cytomegaloviruses (BAY 38-4766): in vitro and in vivo antiviral activity and mechanism of action. J. Antimicrob. Chemother. 48:757-767.
112. Scott, G. M., M. A. Isaacs, F. Zeng, A. M. Kesson, and W. D. Rawlinson. 2004. Cytomegalovirus antiviral resistance associated with treatment induced UL97 (protein kinase) and UL54 (DNA polymerase) mutations. J. Med. Virol. 74:85-93.
113. Seo, S. K., A. Regan, T. Cihlar, D. C. Lin, F. Boulad, D. George, V. K. Prasad, T. E. Kiehn, and B. Polsky. 2001. Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. Clin. Infect. Dis. 33:e105-e108.
114. Sia, I. G., and R. Patel. 2000. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin. Microbiol. Rev. 13:83-121.
115. Simon, M., L. Giot, and G. Faye. 1991. The 3′ to 5′ exonuclease activity located in the DNA polymerase delta subunit of Saccharomyces cerevisiae is required for accurate replication. EMBO J. 10:2165-2170.
116. Smith, I. L., J. M. Cherrington, R. E. Jiles, M. D. Fuller, W. R. Freeman, and S. A. Spector. 1997. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J. Infect. Dis. 176:69-77.
117. Smith, I. L., M. Shinkai, W. R. Freeman, and S. A. Spector. 1996. Polyradiculopathy associated with ganciclovir-resistant cytomegalovirus in an AIDS patient: phenotypic and genotypic characterization of sequential virus isolates. J. Infect. Dis. 173:1481-1484.
118. Smith, I. L., I. Taskintuna, F. M. Rahhal, H. C. Powell, E. Ai, A. J. Mueller, S. A. Spector, and W. R. Freeman. 1998. Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance. Arch. Ophthalmol. 116:178-185.
119. Stanat, S. C., J. E. Reardon, A. Erice, M. C. Jordan, W. L. Drew, and K. K. Biron. 1991. Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir. Antimicrob. Agents Chemother. 35:2191-2197.
120. Studies of Ocular Complications of AIDS Research Group and AIDS Clinical Trials Group. 1996. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. Arch. Ophthalmol. 114:23-33.
121. Sullivan, V., K. K. Biron, C. Talarico, S. C. Stanat, M. Davis, L. M. Pozzi, and D. M. Coen. 1993. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonyl-methoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:19-25.
122. Sullivan, V., C. L. Talarico, S. C. Stanat, M. Davis, D. M. Coen, and K. K. Biron. 1992. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358:162-164.
123. Talarico, C. L., T. C. Burnette, W. H. Miller, S. L. Smith, M. G. Davis, S. C. Stanat, T. I. Ng, Z. He, D. M. Coen, B. Roizman, and K. K. Biron. 1999. Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Antimicrob. Agents Chemother. 43:1941-1946.
124. Tatarowicz, W. A., N. S. Lurain, and K. D. Thompson. 1992. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J. Infect. Dis. 166:904-907.
125. Tatarowicz, W. A., N. S. Lurain, and K. D. Thompson. 1991. In situ ELISA for the evaluation of antiviral compounds effective against human cytomegalovirus. J. Virol. Methods 35:207-215.
126. Telenti, A., and T. F. Smith. 1989. Screening with a shell vial assay for antiviral activity against cytomegalovirus. Diagn. Microbiol. Infect. Dis. 12:5-8.
127. Underwood, M. R., R. G. Ferris, D. W. Selleseth, M. G. Davis, J. C. Drach, L. B. Townsend, K. K. Biron, and F. L. Boyd. 2004. Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob. Agents Chemother. 48:1647-1651.
128. Wang, L. H., R. W. Peck, Y. Yin, J. Allanson, R. Wiggs, and M. B. Wire. 2003. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47:1334-1342.
129. Weinberg, A., D. A. Jabs, S. Chou, B. K. Martin, N. S. Lurain, M. S. Forman, and C. Crumpacker. 2003. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J. Infect. Dis. 187:777-784.
130. Wolf, D., A. Honigman, J. Lazarovits, E. Tavor, and A. Panel. 1998. Characterization of the human cytomegalovirus UL97 gene product as a virion-associated protein kinase. Arch. Virol. 143:1223-1232.
131. Wolf, D. G., C. T. Courcelle, M. N. Prichard, and E. S. Mocarski. 2001. Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Proc. Natl. Acad. Sci. USA 98:1895-1900.
132. Wolf, D. G., D. J. Lee, and S. A. Spector. 1995, Detection of human cytomegalovirus mutations associated with ganciclovir resistance in cerebrospinal fluid of AIDS patients with central nervous system disease. Antimicrob. Agents Chemother. 39:2552-2554.
133. Wolf, D. G., N. S. Lurain, T. Zuckerman, R. Hoffman, J. Satinger, A. Honigman, N. Saleh, E. S. Robert, J. M. Rowe, and Z. Kra-Oz. 2003. Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 101:463-465.
134. Wolf, D. G., I. L. Smith, D. J. Lee, W. R. Freeman, M. Flores Aguilar, and S. A. Spector. 1995. Mutations in human cytomegalovirus UL97 gene confer clinical resistance to ganciclovir and can be detected directly in patient plasma. J. Clin. Investig. 95:257-263.
135. Wolf, D. G., I. Yaniv, A. Honigman, I. Kassis, T. Schonfeld, and S. Ashkenazi. 1998. Early emergence of ganciclovir-resistant human cytomegalovirus strains in children with primary combined immunodeficiency. J. Infect. Dis. 178:535-538.
136. Ye, L. B., and E. S. Huang. 1993. In vitro expression of the human cytomegalovirus DNA polymerase gene: effects of sequence alterations on enzyme activity. J. Virol. 67:6339-6347.
137. Zaia, J. A., G. M. Gallezhawkins, B. R. Tegtmeier, A. Terveer, X. L. Li, J. C. Niland, and S. J. Forman. 1997. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J. Infect. Dis. 176:782-785.
138. Zhang, J., D. W. Chung, C. K. Tan, K. M. Downey, E. W. Davie, and A. G. So. 1991. Primary structure of the catalytic subunit of calf thymus DNA polymerase delta: sequence similarities with other DNA polymerases. Biochemistry 30:11742-11750.
139. Zimmermann, A., D. Michel, I. Pavic, W. Hampl, A. Luske, J. Neyts, E. De Clercq, and T. Mertens. 1997. Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. Antivir. Res. 36:35-42.